The High Affinity Anti-IL-33 Antibody Itepekimab Potently Blocks IL-33 Induced Activation of the ST2/IL-1RAcP Signaling Complex and Inhibits Key Mediators of Airway Inflammation
Asrat S, Zhou Y, Rafique A, Kamat V, Scott G, Birchard D, Ben L, Murphy A, Franklin M, Sleeman M, Orengo J. The High Affinity Anti-IL-33 Antibody Itepekimab Potently Blocks IL-33 Induced Activation of the ST2/IL-1RAcP Signaling Complex and Inhibits Key Mediators of Airway Inflammation. 2024, a6989-a6989. DOI: 10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a6989.Peer-Reviewed Original Research